 This was a double-blinded, randomized, vehicle-controlled study in sporadic superficial BCC sBCC and nodular BCC nBCC patients which consisted of a 21-day screening period, a treatment period of 6 weeks topical 0.75 LDE225 cream application b.i.d ending with post treatment biopsies, as safety visit one week after final study drug administration Day 50, a visit on Day 83 for excision of the treated BCC, and an end of study evaluation Day 90. 